Dec 012022
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
| Tzield | teplizumab-mzwv | 11/18/2022 | To delay the onset of stage 3 type 1 diabetes | Press Release | |
| Elahere | mirvetuximab soravtansine-gynx | 11/14/2022 | To treat patients with recurrent ovarian cancer that is resistant to platinum therapy | Drug Trials Snapshot |
Sorry, the comment form is closed at this time.